Previous 10 | Next 10 |
Lasso announces a significant step forward in healthcare marketing measurement PR Newswire The healthcare marketing and analytics leader expands their Measurement Suite to include unprecedented audience and campaign insights. AUSTIN, Texas , Jan. 3, 2023 ...
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer PR Newswire IQVIA was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials. HOLLISTON, M...
IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a long-term collaboration with Clalit, the largest health services organization in Israel, to launch the fir...
Summary William von Mueffling's 13F portfolio value decreased this quarter from $11.98B to $11.04B. Cantillon increased Microsoft, BlackRock, Entegris, and SS&C Technologies during the quarter. The portfolio continues to be very concentrated with the top five positions acc...
Summary The COVID-19 pandemic's impact on clinical trial delays has expanded the market opportunity for large, multinational CROs. IQVIA, one of the largest CROs, has real opportunities to expand its client base with its Q2 Solutions international offering, technical solutions, R&...
IQVIA Holdings (IQV) Q3 2022 Earnings Conference Call October 26, 2022, 09:00 AM ET Company Participants Nick Childs - Senior Vice President, Investor Relations and Treasurer Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice Presid...
The following slide deck was published by IQVIA Holdings Inc. in conjunction with their 2022 Q3 earnings call. For further details see: IQVIA Holdings Inc. 2022 Q3 - Results - Earnings Call Presentation
IQVIA press release ( NYSE: IQV ): Q3 Non-GAAP EPS of $2.48 beats by $0.10 . Revenue of $3.56B (+5.0% Y/Y) beats by $20M . Adjusted EBITDA of $814 million increased 11.8 percent year-over-year. R&D Solutions quarterly bookings of over $2.5 billion; excl...
Revenue of $3,562 million grew 5.0 percent year-over-year on a reported basis and 10.5 percent at constant currency GAAP Net Income of $283 million grew 8.4 percent year-over-year Adjusted EBITDA of $814 million increased 11.8 percent year-over-year GAAP ...
IQVIA ( NYSE: IQV ) is scheduled to announce Q3 earnings results on Wednesday, October 26th, before market open. The consensus EPS Estimate is $2.38 (+9.7% Y/Y) and the consensus Revenue Estimate is $3.54B (+4.4% Y/Y). Over the last 2 years, IQV has beaten EPS estima...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...